Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Regeneron (GB:0R2M)
LSE:0R2M
Regeneron (0R2M) Share Price & Analysis
1 Followers
0R2M Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$689.00 - $998.57
Previous Close$908.38
Volume25.55K
Average Volume (3M)995.00
Market Cap
$99.59B
Enterprise Value$91.45B
Total Cash (Recent Filing)$10.84B
Total Debt (Recent Filing)$2.70B
Price to Earnings (P/E)N/A
Beta0.67
Next Earnings
May 02, 2024EPS Estimate
$10.19Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding109,761,896
10 Day Avg. Volume782
30 Day Avg. Volume995
Standard Deviation0.10
R-Squared0.02
Alpha0.01
Financial Highlights & Ratios
Price to Book (P/B)3.92
Price to Sales (P/S)4.18
Price to Cash Flow (P/CF)22.40
P/FCF Ratio28.50
Enterprise Value/Market CapN/A
Enterprise Value/Revenue6.97
Enterprise Value/Gross Profit7.50
Enterprise Value/Ebitda19.48
Forecast
1Y Price Target
$1,044.63Price Target Upside18.32% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering22
Regeneron News
Bulls Say, Bears Say
Bulls Say
Drug EfficacyRinvoq showed superior Week 16 efficacy over Dupi in a head-to-head atopic dermatitis study.
Market DemandOverall demand dynamics continue to remain strong with robust growth across all regions.
Product LaunchThe April 1 permanent J-code for Eylea HD is expected to be very important to the success of the launch, as it will likely encourage more prescribers to adopt the drug.
Bears Say
Legal IssuesThe US Department of Justice filed a False Claims Act Complaint against REGN regarding Eylea Medicare drug pricing, potentially costing the Medicare system hundreds of millions of dollars.
Market CompetitionTezepelumab Ph2 showed a modest exacerbation rate reduction, less compared to Dupilumab's rate reduction in similar trials, casting doubts on its competitive edge in the market.
Regulatory ChallengesThe FDA issued a CRL for Regeneron's odronextamab due to misalignment on confirmatory studies, indicating challenges with the drug's approval process.
---
Options Prices
Currently, No data available
---
Ownership Overview
0.00% Insiders
0.00% Mutual Funds
1.84% Other Institutional Investors
98.16% Public Companies and
Individual Investors
0R2M FAQ
What was Regeneron’s price range in the past 12 months?
Regeneron lowest share price was $689.00 and its highest was $998.57 in the past 12 months.
What is Regeneron’s market cap?
Currently, no data Available
When is Regeneron’s upcoming earnings report date?
Regeneron’s upcoming earnings report date is May 02, 2024 which is in 5 days.
How were Regeneron’s earnings last quarter?
Regeneron released its earnings results on Feb 02, 2024. The company reported $11.86 earnings per share for the quarter, beating the consensus estimate of $10.731 by $1.129.
Is Regeneron overvalued?
According to Wall Street analysts Regeneron’s price is currently Undervalued.
Does Regeneron pay dividends?
Regeneron does not currently pay dividends.
What is Regeneron’s EPS estimate?
Regeneron’s EPS estimate is $10.19.
How many shares outstanding does Regeneron have?
Currently, no data Available
What happened to Regeneron’s price movement after its last earnings report?
Regeneron reported an EPS of $11.86 in its last earnings report, beating expectations of $10.731. Following the earnings report the stock price went down -1.733%.
Which hedge fund is a major shareholder of Regeneron?
Among the largest hedge funds holding Regeneron’s share is Dodge & Cox. It holds Regeneron’s shares valued at 2B.
---
Regeneron Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$1,044.63 (18.32% Upside)
$1,044.63 (18.32% Upside)
Blogger Sentiment
Bullish
GB:0R2M Sentiment 100%
Sector Average 70%
Sector Average 70%
Insider Transactions
Sold Shares
Worth $32.2M over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
13.52%
12-Months-Change
Fundamentals
Return on Equity
16.26%
Trailing 12-Months
Asset Growth
13.18%
Trailing 12-Months
Company Description
Regeneron
Founded in 1988, Regeneron Pharmaceuticals, Inc. is a New York-based biotechnology company, which discovers, develops, manufactures, and commercializes medicines for the treatment of various medical conditions. Its product portfolio includes the following brands: EYLEA, Dupixent, Praluent, Kevzara, Libtayo, ARCALYST, and ZALTRAP.
---
0R2M Company Deck
---
0R2M Earnings Call
Q4 2024
0:00 / 0:00
---
0R2M Revenue Breakdown
44.87% EYLEA - U.S.
28.97% Sanofi
11.34% Bayer
4.11% Libtayo - U.S.
10.72% Other
---
0R2M Stock 12 Months Forecast
Average Price Target
$1,044.63
▲(18.32% Upside)
Technical Analysis
Best Analysts Covering 0R2M
1 Year
1 Year Success Rate
23/29 ratings generated profit
1 Year Average Return
+12.58%
reiterated a buy rating 2 months ago
Copying Evan Seigerman's trades and holding each position for 1 Year would result in 79.31% of your transactions generating a profit, with an average return of +12.58% per trade.
---